Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial DNA replication and synthesis proteins comprise the essential multi-protein machinery, often referred to as the replisome, required for the duplication of the bacterial chromosome (NIH, 2017). This complex includes core enzymes such as DNA polymerase III, which executes strand elongation, and DNA helicase (DnaB), which unwinds the double helix (MDPI, 2017). Additionally, type II topoisomerases, specifically DNA gyrase and topoisomerase IV, are critical for managing the topological constraints, such as supercoiling and decatenation, that arise during the replication process (ResearchGate, 2017). These proteins are highly attractive therapeutic targets because they are essential for bacterial viability and possess structural features distinct from their eukaryotic counterparts, allowing for selective toxicity (LibreTexts, 2024). Fluoroquinolones are the most clinically significant class of drugs targeting this system, acting by trapping gyrase and topoisomerase IV in a state that causes lethal double-strand DNA breaks (NIH, 2020). Other agents, such as aminocoumarins, inhibit the process by competitively blocking ATP binding to the gyrase B subunit (ResearchGate, 2017). Emerging therapies, such as novel bacterial topoisomerase inhibitors (NBTIs) and DNA polymerase inhibitors, are being developed to overcome the widespread resistance caused by mutations in these target proteins (NIH, 2026). Targeting this machinery remains a cornerstone of treating a wide range of bacterial infections, though the rise of target-mediated resistance remains a significant clinical challenge (NIH, 2017).
Inhibition of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) by stabilizing cleaved DNA-protein complexes or blocking ATP binding; inhibition of replicative DNA polymerases (PolC, DnaE) and DNA ligase (LigA) to prevent DNA strand elongation and nick sealing.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial DNA replication and synthesis proteins.